Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014) [Health Services and Outcomes]

Conclusion Although symptoms and functional decrements are common among patients with cancer, PRO labeling is rare in the United States, likely because of logistical hurdles and oncology study design. Recent developments within the FDA OHOP to capture PROs in oncology studies for the purpose of product labeling are encouraging.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Outcomes Research Health Services and Outcomes Source Type: research